Medulloblastoma (MB) is the most common malignant brain tumor of childhood arising from deregulated cerebellar development. Sonic Hedgehog (Shh) pathway plays a critical role in cerebellar development and its aberrant expression has been identified in MB. Gene expression profiling of cerebella from 1-to 14-day-old mice unveiled a cluster of genes whose expression correlates with the levels of Hedgehog (HH) activity. From this cluster, we identified Insm1 and Nhlh1/NSCL1 as novel HH targets induced by Shh treatment in cultured cerebellar granule cell progenitors. Nhlh1 promoter was found to be bound and activated by Gli1 transcription factor. Remarkably, the expression of these genes is also upregulated in mouse and human HH-dependent MBs, suggesting that they may be either a part of the HH-induced tumorigenic process or a specific trait of HH-dependent tumor cells. Neoplasia (2008) 10, 89-98 
Introduction
Medulloblastoma (MB) is the most common malignant pediatric brain tumor, whose prognosis has not improved significantly in the last two decades, despite multimodal therapy (surgery, radiation, and chemotherapy), thus justifying the continuous effort in better characterizing the molecular mechanisms involved in tumor initiation and progression [1, 2] .
MB is commonly recognized to originate from cerebellar granule or other precursors that fail to differentiate and keep proliferating [3] . Indeed, the transcriptional pattern of MB is similar to that of the developing mouse cerebellum (5-10 days postpartum), thus supporting the concept that MB is formed from immature cerebellar precursor cells that retain most of the undifferentiated characteristics [4] .
Cerebellar development in mammals largely occurs in the early postnatal period. In mice, proliferation and expansion of the most external layer of the cerebellum, i.e., the external granule layer (EGL), start at birth and peak by 8 to 10 days postpartum (P) [5] . Subsequently, EGL cell proliferation starts exhausting, most of the cells migrate through the molecular and Purkinje cell layers, reach their final resting state, and extend dendrites in the internal granule layer until EGL disappears and differentiation is completed [6] .
A major regulator of this process is the Hedgehog (HH) pathway [7] . Sonic Hedgehog (Shh) is a glycoprotein secreted by Purkinje cells, which binds to the transmembrane receptor Patched (Ptc) on granule cell precursors (GCPs) and, through the activation of downstream transcription factors of the Gli family, promotes proliferation of the EGL progenitors [8] . Interestingly, at the stage of maximal GCP proliferation, HH is maximally activated, as documented by the increase of its target genes such as N-myc, Cyclin D2 (Ccnd2), and PDGFRα [4, 9] .
Aberrant activation of the Shh pathway has been linked to MB formation [10, 11] . Germline mutation of Ptch1 (the Shh receptor which acts as a repressor in the absence of the ligand) is responsible for the Gorlin syndrome that exhibits high MB incidence [12] . Mutations of the HH pathway negative regulators (e.g., Ptch1, SuFu, and Ren/KCTD11) were also reported in sporadic MB (reviewed in the works of Wetmore _Hlt183838176[ [10] , Ferretti et al. [11] , and Di Marcotullio et al. [13] ), as well as in the upregulation of Shh target genes, such as Gli1 [10] . Similarly, different mouse models that exhibit increased rate of MB underscore the direct relationship between Shh/Ptc1 signaling and MB [10] . Shh transcriptional targets involved in the mitogenic response of mice GCPs (e.g., Ccnd2 and N-myc) were confirmed to be implicated in MB development [14, 15] , further highlighting the role of altered Shh signaling in MB.
To further characterize the contribution of the HH pathway in cerebellar development and MB and to search for novel Shh targets potentially useful for patient stratification and/or molecular therapies we: 1) used gene expression profiling of mouse cerebella at different time points during postnatal development (P1 through P14) to identify subsets of genes specifically upregulated in the time window in which HH pathway is strongly activated; 2) selected several of these genes and verified if they are induced in cultured cerebellar GCPs treated with Shh; and 3) analyzed mouse and human MB samples for the expression levels of these genes.
Through this approach, we have identified Insm1 and Nhlh1/ NSCL1 as new HH target genes that are overexpressed in MB. Through the identification of functional Gli binding sites on the promoters of mouse and human Nhlh1, we also highlighted a direct regulation of this gene by Gli transcription factors.
Materials and Methods

Tissue Samples, Cell Cultures, and Treatments
Surgical specimens of human MBs were collected with the approval of the Institutional Review Board. Control human cerebella RNA were from Biocat (Heidelberg, Germany) and Ambion (Foster City, CA).
Mouse cerebella and MB specimens were obtained from wild-type and Ptc1 +/− CD1 mice [16] . Animal handling was according to the guidelines of Sapienza University of Rome. Mouse GCP cultures were prepared cultured and treated as previously described [17] . Recombinant Shh N-terminal peptide was from R&D Systems (Minneapolis, MN).
HEK293T cells were maintained in DMEM containing 10% FBS, glutamine, and antibiotics.
Microarrays and Real-Time Quantitative Polymerase Chain Reaction Analysis
Total RNA from P1 to P14 mice cerebella (six mice at each time point) was used. RNA extraction, cDNA synthesis, cRNA labeling, hybridization, and scanning were performed according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). For each of the duplicate microarray hybridization, RNA from three mice of the same time point was pooled. GeneChip Murine Genome U74Av2 Set microarrays (Affymetrix) were used in all microarray ex-periments. Data analysis was performed using Time-Course Experiment AMDA version 2.1.0 (Milan, Italy).
Real-time quantitative polymerase chain reaction (QPCR) was performed as previously described [13] using the ABI Prism 7900HT System (Applied Biosystems, Monza, Italy), with Assay-on-Demand reagents (Applied Biosystems). mRNA quantification was expressed in arbitrary units as sample/calibrator ratio or sample/mean of controls ratio. All values were normalized to endogenous controls: glyceraldehyde-3-phosphate dehydrogenase, β-actin, and hypoxanthineguanine phosphoribosyltransferase.
Constructs and Luciferase Assays
pGL4 and pRLTK reporters were from Promega (Madison, IL). pGL4-5xmutGliBS, pGL4-5xmGliBS, pGL4-3xhGliBS, and pGL4-5xhGliBS were generated by ligation of synthetic oligos (sequences are shown in Figure 4A ) into pGL4. pCMVGliHA was previously described [13] . Flag-tagged Gli1 was cloned into pCDNA (Invitrogen, Carlsbad, CA) by PCR using the Not I site. pGEX-GliZF was cloned by PCR and fused in-frame in pGEX4t3 (Amersham, Milan, Italy). All constructs were verified by sequencing.
For luciferase experiments, HEK293T cells were transfected with Lipofectamine 2000 (Invitrogen, Milan, Italy) according to the manufacturer's instructions. About 24 to 48 hours later, luciferase assay was performed using a dual-luciferase kit (Promega, Milan, Italy).
Electrophoretic Mobility Shift Assay
The double-stranded DNA fragments corresponding to the mouse and human promoter regions ( Figure 3A ) were PCR-amplified and purified by electrophoresis and gel extraction kit (Qiagen, Milan, Italy). The canonical Gli binding sequence ( Figure 3A ) was produced by annealing complementary oligos. Fragments were 32 P-labeled, purified through G30 columns (Amersham Pharmacia, Milan, Italy), and used for electrophoretic mobility shift assay (EMSA).
Nuclear extracts were prepared from 293T cells transfected with pCDNAFlagGli1 or an empty vector. Glutathione S-transferase (GST) fusion proteins were produced in BL21 cells following isopropylβ-D-1-thiogalactopyranoside (IPTG) induction, cell lysis, and binding to glutathione-agarose beads (Amersham Pharmacia) according to manufacturer's instructions.
EMSA was performed according to standard procedures. Binding reactions contained 20,000 counts per minute 32 P-labeled probe and 15 μg nuclear extract (or the indicated amount of GST fusion protein) in binding buffer. In some experiments, 2 μg of rabbit anti-GLI1 (H-300; Santa Cruz Biotechnology, Santa Cruz, CA) or mouse anti-FLAG-M2 (Sigma) antibodies were added to the sample. Competition experiments were performed by adding 50× or 100× molar excess of cold oligonucleotides. Complexes were resolved on a non-5% PAGE, dried, and exposed for autoradiography.
Western Blot Analysis
Tissue samples were lysed in standard radioimmunoprecipitation assay buffer plus protease inhibitors (Roche, Mannheim, Germany). Lysates were separated on SDS-PAGE and immunoblotted using standard procedures. Anti-NSCL1 (AB5698; Chemicon, Milan, Italy), anti-β-actin, and HRP-conjugated secondary antisera (Santa Cruz Biotechnology, Heidelberg, Germany) were used, followed by enhanced chemiluminescence (ECL; Amersham).
Results
Gene Expression Profiling of Developing Mouse Cerebellum
Quantitative analysis of Gli1 mRNA expression levels throughout mouse postnatal development shows a peak between P7 and P10 ( Figure 1A) , indicating the highest HH pathway activation in this timeframe.
Because putative HH target genes are expected to be regulated in an overlapping period, we have analyzed gene expression in mouse cerebella during the first 2 weeks of development, by means of the Gene-Chip Murine microarray (Affymetrix). RNA samples obtained from six mice cerebella collected at each time point (P1, P2, P7, and P14) were used. Analysis of about 12,000 genes present in the microarrays allowed us to identify several clusters of genes with diverse trends of expression during cerebellar development ( Figure 1B and not shown). We focus here on the analysis of a subset of genes specifically upregulated between days 2 and 14, with a peak around day 7, and reduced expression afterwards ( Figure 1B ). As expected, some of the genes that belong to this cluster are known targets of HH pathway (e.g., Ccnd2, PDGFRα, N-myc, and Gli1 itself [18, 19] ) ( Figure 1C ). Table W1 shows a selection of the most strongly modulated genes belonging to this cluster.
The developmentally regulated expression of several genes (including HH targets such as Ccnd2) was further confirmed by QPCR analysis on the same mRNA samples used in the microarrays (representative experiments in Figure 1D and not shown). Between the most strongly upregulated genes were the transcription factors neural basic helixloop-helix 1 (Nhlh1) [20] and insulinoma-associated 1/IA-1 (Insm1) [21] ( Figure 1D ).
Gene Expression Analysis in Shh-Treated Cultured Cerebellar GCPs
The main cerebellar HH target cell is the GCP, which also represents the most abundant cerebellar cell population. Therefore, following the hypothesis that several genes upregulated at P7 during cerebellar development should also be HH targets, we measured expression levels in primary GCPs (from P4 mice) cultured in the presence or in the absence of recombinant Shh-N protein. A significant increase in Gli1 and Ccnd2 mRNA levels confirmed the HH activa-tion in Shh-treated GCPs ( Figure 2 , A and D). Nhlh1 levels in control GCPs decrease significantly throughout the time of culture (from 24 to 96 hours) ( Figure 2B ), suggesting that Nhlh1 expression is sustained by in vivo signals that are progressively lost during the in vitro culture. One of these in vivo signals is represented by Shh: in fact, the addition of Shh antagonizes silencing of the Nhlh1 gene in cultured GCPs, suggesting that Shh activates Nhlh1 transcription ( Figure 2B ). Moreover, Insm1 expression levels significantly increase upon Shh treatment ( Figure 2C ), whereas the levels of several additional genes examined, including Pax6 (Figure 2E ) , Nfib, and HK2 (data not shown), were not significantly modulated.
These data suggest that Nhlh1 and Insm1 are targets of the HH signaling pathway.
Nhlh1 Is a Direct Target of Gli1 Transcription Factor
We next analyzed Insm1 and Nhlh1 promoter regions for the presence of putative Gli-responsive sites. Whereas analysis of the Insm1 promoter did not reveal potential Gli binding sites (not shown), analysis of the promoter region of mouse Nhlh1 allowed the identification To verify whether Nhlh1 promoter was actually bound by Gli1, we performed EMSA using nuclear extracts from Flag-tagged Gli1-transfected 293T cells and a DNA probe containing the mouse promoter fragment spanning between −736 and −615 bp (shown in Figure 3A ). Figure 3B shows that Gli1 binds the promoter fragment (mNhlh) and this binding is competed by either a 50× cold probe excess or addition of anti-Gli1 or anti-Flag antibodies. The presence of a Gli-promoter complex was confirmed by the efficient Figure 3 . Gli transcription factor binds in vitro to the putative Gli-binding sequences on the Nhlh1 promoters. (A) Mouse (1) and human (2) Nhlh1 promoter sequence containing the Gli-responsive regions (underlined). Sequence (3) is a canonical GliBS-containing fragment [22] . Double-stranded oligonucleotides containing these sequences were used in the following EMSA. (B) EMSA of the mouse Nhlh probe (P) was performed using lysates from cells transfected with Gli1-Flag-expressing vector. The shifted complex (S) is competed with a 50× excess of cold probe or by incubation with antibodies α-Gli1 or α-flag. and quantitative binding of recombinant GST-fused Gli1 zinc-finger to the mNhlh probe (which was competed by a 100× excess cold probe), whereas the corresponding GST alone did not bind at all (Figure 3C ) . As a positive control, binding of a canonical GliBS-containing fragment [22] to the same GST-Gli1 protein indicates a comparable affinity of the two using the human Nhlh1 promoter probe (hNhlh: position −730/−607), whose complex with GST-Gli1 was competed by an excess of cold probe ( Figure 3D ), whereas GST alone failed to bind DNA.
To verify whether the interaction between Gli1 and these Glibinding sites was able to trigger transcription, luciferase reporter constructs containing the Gli-binding sites from either mouse (mNhlh-GliBS) or human (hNhlh-GliBS) Nhlh1 promoters ( Figure 4A ) were used in luciferase assays. mNhlh-GliBS reporter increased luciferase levels following cotransfection with increasing amounts of Gli1 vec-tor, whereas activity of mutant GliBS (mutGliBS, unable to bind Gli1) or the empty reporter was not modulated ( Figure 4B ). Similarly, human GliBS reporters significantly enhanced luciferase transcription in response to increasing amounts of transfected Gli1 ( Figure 4C ) .
These results indicate that Nhlh is a direct target of HH signaling pathway and is transcriptionally activated by Gli1.
Expression Analysis of Insm1 and Nhlh1 in MB Samples
To test whether Insm1 and Nhlh1, modulated during cerebellar development, could also be relevant in MB, we evaluated their expression in tumors obtained from Patched1 +/− mice (Ptc +/− ) in which GCPs develop HH-dependent MB due to the loss of the receptor Ptc, which leads to the constitutive activity of the pathway [16, 23] .
Confirming HH pathway activation in these tumors, all MB from Ptc +/− animals exhibited high levels of HH activity compared to adult and P7 cerebella as documented by Gli1 ( Figure 5D ) and Ccnd2 mRNA levels ( Figure 5C ). Remarkably, we observed a dramatic increase of both Insm1 and Nhlh1 mRNA levels in all MBs ( Figure 5 , A-C ), suggesting that HH-triggered expression of these genes is conserved during cerebellar tumorigenesis in vivo. The high Nhlh1 levels expressed in mouse MB samples were also mirrored by increased protein levels when compared either to normal adult control ( Figure 5E ) or to primary granule cells obtained from P4 mice cerebella ( Figure 5F ). Interestingly, relative levels of Nhlh1 protein samples from P2 and P7 cerebella controls were higher than in adult, in keeping with mRNA expression levels shown in Figure 1D .
Next, we investigated whether the deregulated expression of Insm1 and Nhlh1 observed in mouse HH-dependent MB was also relevant in the multifactorial carcinogenesis of sporadic human MBs. To this purpose, we analyzed a set of 16 human sporadic MBs ( Figure 6 ). Insm1 was expressed at higher levels in tumors compared to either adult (P < .05) or fetal cerebella ( Figure 6A ). Likewise, Nhlh1 was overexpressed in all tumor samples compared to adult (P < .005) and fetal cerebella ( Figure 6B ).
Most MBs respond to the HH inhibitor cyclopamine with a block of proliferation, implying a certain degree of basal HH activity [19] . However, we recently reported that human sporadic MBs might be subclassified as low-or high-Gli1-expressing, indicating a different level of HH activation [17] .
We have therefore subdivided our series of MBs in two subsets: MBs with Gli1 levels at least two standard deviations above the mean value of the adult cerebella (Gli high subset) and MBs with Gli1 levels within or below the range of normal cerebella (Gli low ) ( Figure 6C ). We then analyzed Insm1 and Nhlh1 levels in these two subsets. Although Insm1 levels in the Gli high subset were more significantly increased (P < .02) compared to adult cerebella, we could not correlate Gli1 and Insm1 expression levels on the whole MB population (Figure 6D) , because of the high Insm1 levels found frequently in Gli low tumors ( Figure 6 , A and C ), suggesting a more complex regulation of Insm1 in MB, in addition to HH control. Instead we found a significant correlation between Gli1 and Nhlh1 levels (P < .02) in the two MB subset ( Figure 6E ), consistent with a direct role of HH in the regulation of Nhlh1 expression.
Discussion
Our work identifies the developmentally regulated genes Insm1 and Nhlh1 as novel targets of HH activity. Most relevantly, the expression [22] and Gli-binding sites on mouse and human Nhlh promoters (mNhlh-GliBS and hNhlh-GliBS, respectively). At the bottom, a mutated binding site (mutGliBS) was used as a negative control. (B) Activation of a mNhlh-GliBS luciferase reporter (five copies of the sequence), following cotransfection with increasing amounts (5, 20 , and 50 ng) of Gli1-expressing vector. Empty reporter and mut-GliBS (five copies) are cotransfected as a control with 50 ng of Gli1 plasmid. (C) Same assay as in (B), but using hNhlh-GliBS (three or five copies) and mutGliBS as reporters (average ± SD from at least three experiments). of these genes is upregulated in both mouse and human MBs, in which HH pathway is activated, suggesting that they may be either a part of the HH-induced tumorigenic process or a specific trait of HH-dependent tumor cells.
Insm1 encodes a zinc-finger DNA-binding protein and exhibits a restricted expression pattern, including fetal brain [21, 24] , pancreas [25] , and neuroendocrine tumors [21, 26] .
We report here on the activation of Insm1 expression by HH signaling. The Insm1 promoter does not present Gli-binding sites, suggesting that the mechanisms of activation by Shh may be due either 1) to the presence of Gli-binding sites in other cis-regulatory regions of the gene or 2) to indirect regulation, through some yet unidenti-fied intermediate transcription factors. To date, the transcriptional activation of Insm1 in neuroendocrine tissues and tumors has been attributed to the formation of basic helix-loop-helix (bHLH) protein heterodimers, NeuroD/E47 and neurogenin3/E47 [27] , on the E-box of Insm1 promoter [24, 28] . Whether these factors are involved in the regulation of Insm1 by HH remains to be elucidated.
Interestingly, the link between HH pathway and Insm1 we have shown in brain tumors is consistent with the Insm1 expression in the majority of small cell lung cancers [26] , which also exhibit a high frequency of HH pathway activation [29] . Furthermore, increased Insm1 had been previously detected in desmoplastic MB, together with N-myc, Ptc, and Gli1, which well fits with increased HH activation in this subclass of MB [30] . The biologic functions of Insm1 are not well defined: it has been shown that Insm1 acts as a transcriptional repressor on NeuroD and on Insm1 itself, generating an autoregolatory loop [31] . It was also shown that Insm1 is required for the differentiation of endocrine pancreas [25, 28] , whereas its role in cerebellar or neuronal development has not been identified yet [25] . Likewise, the role of Insm1 in MB needs to be clarified. The regulatory loop between Insm1 and NeuroD, a factor important in the differentiation and survival of postmitotic cerebellar granule cells, may explain, in part, its role in neuronal development and tumorigenesis [32] .
As for the second HH target Nhlh1, this gene was originally cloned because of its homology within the bHLH motif to the oncogenic hematopoietic transcription factor SCL/Tal1 [20] . Nhlh1 belongs to class II of the bHLH protein family of transcriptional regulators [27] . Class II bHLHs exhibit tissue-restricted expression and some of them (e.g., neurogenin, NeuroD, and Math1) are expressed in neuronal cells and are involved in the specification of neuronal lineages. Nhlh1 acts as a transcriptional repressor through dimerization with E47 (a class I bHLH) and interacts with the Lim-only family members LMO4 and LMO2 that modulate its activity [33] .
So far, analysis of Nhlh1 transcripts [20, 34] or use of lacZ reporter [35] indicate that Nhlh1 expression is confined to the nervous system. Nhlh1 expression has been observed in both the embryonic and postnatal developing cerebellum. Between E14.5 and E18.5, Nhlh1 expression is restricted to migrating GCP of the cerebellar epithelium, which originates from the rhombic lip to form the EGL [35, 36] . Postnatally, Nhlh1 is expressed in the premigratory zone of the EGL with maximal expression between P7 and P10 [37] , in agreement with our findings (Figure 1D ). At P10, Nhlh1 transient expression is also detected in the newly formed internal granule layer [35] , suggesting that it may be involved in GCP proliferation and in the onset of differentiation, but not in the maintenance of the differentiated state [36] .
Such a role at the beginning of the differentiation process is also supported by the expression pattern of Nhlh1 in early differentiating embryonic neuroblasts, where Nhlh1 is expressed in cells that have just become postmitotic [34] . Interestingly, expression of Nhlh1 in postmitotic neurons has to be downregulated when the cells have migrated to their final position to allow them to become differentiated [34] .
The identification of Nhlh1 as a novel target of HH pathway, underscores its potential role in the activity of Shh. HH signaling plays a complex role in driving the development of lineage-committed cerebellar GCPs, being mostly responsible for the expansion of an early pool of progenitor cells, which, subsequently, terminally differentiate into postmitotic mature granule cells. HH window of activity is overlapping with the expression of Nhlh1, suggesting that this regulatory loop might be involved in the transition from proliferation to early differentiation of progenitor cells.
Whether this process may be relevant for cerebellar tumorigenesis, which stems from disequilibrium between proliferation and differentiation of GCP, is an outstanding question that needs to be appropriately addressed. We have described a deregulated expression of Nhlh1 in both human and murine MB, with increased levels of both mRNA and protein. Furthermore, we show that Nhlh1 expression correlates with the strength of HH pathway activity. Nhlh1 expression may be a feature of HH-dependent tumors in which a deregulation of the signals sustaining the transition from proliferation toward differentiation of GCP would have occurred during the tumorigenic process. These may speculatively include uncoordinated activation versus silencing of Nhlh1 at the proliferation/differentiation transition of early developing GCP or aberrant interactions with other bHLH partners.
In conclusion, by combining gene expression analysis during postnatal development with patterns of gene expression in response to HH signaling pathway and in HH-dependent cerebellar tumors, we have identified novel HH target genes that might provide insights in the molecular events that underlie the neoplastic transformation of neuronal progenitor cells at the critical stage of early development. Ratios between signal at P7 and signal at P2 and P14/P7 are indicated. Numbers are averages from duplicate experiments. Only genes modulated more than 2.5-fold are shown. 
